本文へ移動
cccskills
無料GitHub で公開

hypercalcemia-diagnostic-algorithm

Work up a patient with confirmed hypercalcemia using the PTH-dependent vs. PTH-independent algorithm — order the right second-tier tests (PTHrP, 25(OH)D, 1,25(OH)2D, SPEP/UPEP, urinary calcium/creatinine clearance ratio, TSH) to reach a diagnosis. Trigger when a clinician asks "what's causing this hypercalcemia", "how to work up high calcium", "what tests to order for hypercalcemia", "PTH is normal what next", "differential diagnosis of hypercalcemia", or shares a confirmed hypercalcemia and asks for the workup.

インストール方法を見る

含まれるファイル(1)

  • SKILL.md6.1 KB

SKILL.md(原文)

インストールする前に、エージェントに与えられる指示の中身を確認できます。

Hypercalcemia — Diagnostic Algorithm

Use this skill once hypercalcemia is confirmed (corrected or ionized Ca elevated on ≥2 occasions). The pivot is PTH — it splits the differential cleanly.


STEP 1 — Order the first-tier panel

For every hypercalcemic patient, order on day one:

  • Corrected total calcium + ionized calcium
  • Intact PTH (2-site assay — current standard)
  • 25(OH)D and 1,25(OH)2D
  • Phosphate, magnesium
  • Creatinine + eGFR
  • 24-h urine calcium and creatinine (calculate Ca/Cr clearance ratio)
  • Albumin
  • CBC, ALP, LFTs

Then proceed to Step 2 based on PTH.


STEP 2 — Pivot on PTH

Branch A: PTH is HIGH or INAPPROPRIATELY NORMAL → PTH-dependent

A normal PTH in the setting of hypercalcemia is not normal — PTH should be suppressed. Treat as elevated.

Order:

  • 24-h urinary Ca/Cr clearance ratio
    • Formula: (Urine Ca × Serum Cr) / (Serum Ca × Urine Cr)
    • <0.01 → suspect FHH — do not operate; consider CaSR genetics, family screening
    • >0.02 → consistent with PHPT
  • Medication review — lithium, thiazides, teriparatide can mimic PHPT
  • Family history — MEN1 (parathyroid + pituitary + pancreas), MEN2A (parathyroid + medullary thyroid + pheo), MEN4, HPT-JT (jaw tumour + renal cysts)

Likely diagnoses:

  • Sporadic primary hyperparathyroidism (most common, 85–90% single adenoma)
  • Familial PHPT / MEN1, 2A, 4 / HPT-JT if family history positive
  • Familial Hypocalciuric Hypercalcemia (FHH) if Ca/Cr clearance <0.01
  • Tertiary hyperparathyroidism (CKD, post-renal-transplant)
  • Lithium- or thiazide-induced
  • Ectopic PTH secretion (rare — ovarian, lung, thyroid, thymus, gastric)

Confirm PHPT: two elevated corrected (or ionized) Ca + non-suppressed PTH at least 2 weeks apart.

If diagnosis = PHPT and surgery planned: pre-op imaging (MIBI ± ultrasound), DXA (lumbar spine, hip, distal 1/3 radius), VFA / vertebral X-ray, baseline 24-h urine Ca, eGFR.


Branch B: PTH is LOW / SUPPRESSED → PTH-independent

The differential is malignancy, vitamin D excess, granulomatous disease, endocrine disorders, or medication.

Order on top of the first-tier panel:

  • PTHrP (drives MAH workup)
  • SPEP + UPEP + serum free light chains (rule out myeloma)
  • TSH (hyperthyroidism)
  • Cortisol / ACTH stimulation if hypoadrenalism suspected
  • Vitamin A level if dermatologic / neoplastic retinoid use
  • Chest X-ray ± CT chest (sarcoid, granulomatous disease, lung cancer)
  • Skeletal imaging (X-ray skeletal survey, bone scan, or CT/MRI as guided)
  • Medication / supplement history including OTC

Then sub-classify:

B1. PTHrP elevated → Malignancy-Associated Hypercalcemia (MAH)

  • Squamous cell tumours (lung, head & neck, oesophagus, cervix, vulva, skin)
  • Renal cell, bladder, ovarian carcinoma
  • Breast cancer with bone mets
  • ATL (HTLV-1), non-Hodgkin lymphoma
  • Hypercalcemia is usually a late, advanced-stage finding → search the obvious primary first.

B2. 1,25(OH)2D elevated → Vitamin D activation excess

  • Granulomatous disease — sarcoidosis, TB, fungal (histoplasmosis, coccidiomycosis, cryptococcosis), berylliosis, GPA, Crohn's, eosinophilic granuloma, Langerhans cell histiocytosis, cat-scratch
  • Lymphoma (Hodgkin, NHL) — extrarenal 1α-hydroxylase
  • CYP24A1 inactivating mutation (idiopathic infantile hypercalcemia in adults)

B3. 25(OH)D very high → Vitamin D toxicity

  • Excess vitamin D / D2 / D3 / calcitriol intake.

B4. SPEP/UPEP positive → Multiple myeloma

  • ~30% of myeloma patients develop hypercalcemia (usually with renal failure / Bence-Jones nephropathy).
  • Confirm with bone marrow biopsy; mm-diagnostic-workup skill.

B5. PTHrP, 1,25(OH)2D, SPEP all normal → consider:

  • Hyperthyroidism (TSH suppressed)
  • Adrenal insufficiency
  • Pheochromocytoma, VIPoma, acromegaly (rare)
  • Medication — see the medication-induced-hypercalcemia-screener skill
  • Immobilisation, rhabdomyolysis (polyuric phase), milk-alkali
  • Vitamin A excess

STEP 3 — Document & act

Once diagnosis is established:

  • Confirm with at least two values 2 weeks apart for chronic disorders (PHPT, FHH).
  • Treat the underlying cause; if Ca > 12 with symptoms or > 14 in any case → use the acute-hypercalcemia-management skill.
  • For PHPT, evaluate end-organ involvement (DXA, VFA, renal imaging, eGFR, 24-h urine Ca) before surgery.

CLINICAL GUARDRAILS

  • A "normal" PTH in a hypercalcemic patient is inappropriate. Treat as PTH-dependent.
  • Always check the urinary Ca/Cr clearance ratio in PTH-dependent hypercalcemia before referring for parathyroidectomy — FHH is operatively futile and surgery is harmful.
  • Lithium and thiazides can cause a PTH-dependent picture that mimics PHPT — review meds before booking surgery. The hypercalcemia is reversible on stopping the drug.
  • Hypercalcemia in malignancy is almost always late-stage. The cancer is rarely occult — look hard, but expect to find it.
  • Multiple myeloma is missed if SPEP alone is ordered. Always pair with UPEP and serum free light chains.
  • Granulomatous hypercalcemia is sun-/season-dependent — patients with sarcoid often get hypercalcemic in summer or after a small dose of vitamin D supplement.
  • Bone scan can be falsely negative in myeloma — use whole-body low-dose CT or PET-CT.

SOURCE

Bilezikian JP, Endotext. Approach to Hypercalcemia. NCBI Bookshelf NBK279129. Section: Hypercalcemic Disorders; Clinical Assessment; Figure 8.

レビュー

まだレビューはありません。使ってみた感想をお寄せください。

同じリポジトリのスキル

概要と使いどころ

Guide pump setting adjustments for the MiniMed 780G system based on CareLink data, using Medtronic's 3-step follow-up workflow. Use when a clinician has CareLink data for a 780G patient and wants to know what to change — which setting, by how much, and how to program it. Triggers include: "what do I adjust", "how to fix high TIR", "how to reduce hypos", "adjust ICR/ISF/basal", "SmartGuard settings", "780G pump settings review", or any question about optimising 780G therapy after reviewing a download.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL122026年10月5日 更新

Performs corticotropin stimulation test to diagnose adrenal insufficiency when morning cortisol is indeterminate (3-15 µg/dL). Triggers include morning cortisol 3-15 µg/dL requiring further AI testing.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL122026年10月5日 更新

Administers immediate parenteral injection of 50–100 mg hydrocortisone for suspected adrenal crisis secondary to adrenal insufficiency. Triggers include hypotension, hypoglycemia, or acute illness in a patient with known adrenal insufficiency.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL122026年10月5日 更新

Clinicians educate adrenal insufficiency patients taking nondexamethasone glucocorticoids who initiate enzyme-inducing antiepileptic drugs about early signs of adrenal insufficiency. Trigger when an AI patient on nondexamethasone GC starts an enzyme-inducing AED such as phenytoin, carbamazepine, or oxcarbazepine.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL122026年10月5日 更新

In central hypothyroidism patients receiving levothyroxine who initiate enzyme‑inducing antiepileptic drugs, the guideline recommends checking free T4 at least 6 weeks after AED start and increasing the levothyroxine dose if free T4 falls below the target range. Triggers include: central hypothyroidism patient on levothyroxine starting antiepileptic drug such as phenytoin, carbamazepine, or oxcarbazepine.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL122026年10月5日 更新

Applies serum cortisol cutoffs (<3 μg/dL indicates central adrenal insufficiency; >15 μg/dL likely excludes it) when evaluating morning cortisol for suspected adrenal insufficiency. Triggers include morning cortisol measurement in suspected AI and use when interpreting morning cortisol levels for adrenal insufficiency workup.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL122026年10月5日 更新

dromlakhani のスキルをすべて見る

このスキルの問題を報告する